SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 9.99% Stake in BioXcel Therapeutics
Beneficial Ownership Report
Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a significant beneficial ownership stake of 9.99% in BioXcel Therapeutics, Inc. as of December 31, 2024.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed a Schedule 13G indicating beneficial ownership in BioXcel Therapeutics, Inc.
- As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 4,997,275 shares of BioXcel Therapeutics' Common Stock.
- This ownership represents 9.99% of the total outstanding shares of BioXcel Therapeutics' Common Stock.
- Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is deemed to beneficially own the shares held by the Master Fund.
- The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the company's operational or financial performance.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
This document is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the issuer's future performance or outlook.
Industry Context
This filing reflects a significant ownership stake by an institutional investor in a biotechnology company. Such disclosures are common and provide transparency into major shareholder positions, which can sometimes signal investor confidence or strategic interest in the sector, though this specific filing does not provide details beyond the ownership itself.
Related Party Transactions
- Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares. Steven Boyd is the managing member of Armistice Capital, LLC, establishing a relationship between the reporting persons and the fund holding the shares.
Stakeholder Impact
- Shareholders: The disclosure of a significant 9.99% stake by an institutional investor provides transparency regarding the company's ownership structure and may influence investor perception or trading activity.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires the filing of this statement, indicating the beneficial ownership stake as of this date. |
| 02/14/2025 | Date the Schedule 13G statement was signed and filed with the SEC. |
Keywords
BioXcel Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.